49 results about "Delirium" patented technology

The invention discloses a novel traditional Chinese medicine composite for treating coma and heart syncope symptoms and a preparation method thereof. The traditional Chinese medicine composite mainly comprises the following raw material medicines: styrax, benzoin, holy basil, rhizoma acori graminei, toad venom, tambac, santalwood, rosa banksiae, nutgrass flatsedge, toosendan fruit, radix aristolochiae, common fibraurea, macrostem onion, fructus citri sarcodactylis, citron, aspongopus, lotus node, madder, dalbergia wood, plant soot, rhizoma ligustici wallichii, corydalis tuber, turmeric, curcuma, mastic, myrrh, radix salviae miltiorrhizae, peach kernel, safflower, radix notoginseng, ground beetle, stiff silkworm, logwood, draconis sanguis, catechu, rhizoma sparganii, rhizoma zedoariae, pangolin scales, spatholobus stem, motherwort, angelica, rhizoma atractylodis, radix puerariae, angelica root, sibirian button bur, magnolia flower, purple common perilla, chrysanthemum, baikal skullcap root and coptis root. The traditional Chinese medicine composite can be prepared into any common oral preparation according to a conventional traditional Chinese medicine preparation method. The invention can obviously improve diseases which are caused by the inverse disorder of the functional activities of qi, fluctuation warp and non-smooth qi of yin and yang and represent coma, delirium, exanimation and asphyxia as main symptoms or are accompanied with the symptoms of asphyxia and coldness of limbs, dottiness and the like, and has definite clinical curative effect, obvious curative effect and quick acting. Because the traditional Chinese medicine composite basically adopts medicine-food homologous medicines specified by the national dispensatory for combination, the traditional Chinese medicine composite has the advantages of low expense, no toxic or side effect basically and the like.

Provided are a histamine-H3 receptor antagonist; and a preventive and / or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute / congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnia, repetitive hypersomnia, true hypersomnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder, and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit / hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X1 and X2 independently represent a nitrogen atom or CH; Y represents a specific group; X3 represents Os—(CH2)m; R1 and R2 independently represent a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, or an acetyl group substituted with 2 or 3 fluorine atoms; s is 0 or 1; and m is an integer to make (m+s) 0 or from 1 to 4], or its pharmaceutically-acceptable salt.

Provided are a histamine-H3 receptor antagonist; and a preventive and / or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute / congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnnia, repetitive hypersomnnia, true hypersomnnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder, and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit / hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X1 and X2 independently represent a nitrogen atom or CH; Y represents a specific group; X3 represents Os—(CH2)m; R1 and R2 independently represent a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, or an acetyl group substituted with 2 or 3 fluorine atoms; s is 0 or 1; and m is an integer to make (m+s) 0 or from 1 to 4], or its pharmaceutically-acceptable salt.

The invention discloses a method for screening, evaluating and intervening senile syndromes of hospitalized senile patients, which comprises the following steps of: comprehensively screening the senile syndromes of the senile patients; carrying out special assessments including pressure sore risk degree, disability degree, emotional disorder degree, sleep quality, cognitive disorder degree, malnutrition degree, dysphagia degree, defecation and urination, social support, pain, delirium, tumble, sarcopenia, weakness, body diseases and the like; and making individualized intervention suggestions according to the evaluation conclusion. According to the invention, elderly health management is associated with different states of diseases, an elderly syndrome intelligent management method is provided for elderly patients in a targeted manner, and disease hierarchical management and continuous service are realized. The method comprises a complete process of health information collection, disease and function evaluation, intervention opinions and follow-up visits, so that the method can be widely popularized as a special diagnosis and treatment technical method of the elderly medical inpatient department, and can enable the elderly to obtain better standard, effective and homogenized services.

Intended to prevent self-extubation of nasal or oral tubes of an awake patient who may reflexively attempt removal of such and allow the early mobilization and exercise necessary for preservation of as much muscle strength as possible, promotion of diaphragmatic motion necessary for liberation from a ventilator, reduction of patient stress allowing for sedation minimization and improved cognition for reduction of delirium and post-intensive care syndrome, and relief of medical staff and healthcare dollars to focus more on healthcare rather than on protection from self-harm.

The present invention relates to novel compounds of formula (I) useful as MCH receptor antagonists. These compounds are useful in pharmaceutical compositions for the prevention or therapeutic improvement of memory dysfunction, sleep and wakefulness disorders, anxiety, depression, mood disorders, seizures, obesity, diabetes, appetite and food intake Abnormalities, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorder (including bulimia), anorexia, psychosis (including manic depression), schizophrenia, delirium, dementia, catatonia, cognitive impairment , attention deficit disorder, substance use disorder, movement disorders (including Parkinson's disease), epilepsy, and addiction.

The present invention relates to a monitoring system (1, 2, 3) and a corresponding monitoring method for monitoring a patient and detecting delirium of the patient in an unobtrusive manner without the need of on-body sensors. The proposed monitoring system comprises a monitoring unit (10) for obtaining image data (30) of the patient over time, an image analysis unit (12) for detecting motion events of the patient from the obtained image data (30), an evaluation unit (14) for classifying the detected motion events into delirium-typical motion events and non-delirium-typical motion events, and a delirium determination unit (16) for determining a delirium score (32) from the duration, intensity, type, location and / or occurrence of delirium-typical motion events, said delirium score (32) indicating the likelihood and / or strength of delirium of the patient.

This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for treating delirium. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for treating delirium in a human including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.

The present invention encompasses novel substituted pyrimidine compounds of Formula (I): which act as MCH receptor antagonists. These compounds are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

The present invention relates to novel compounds of Formula (1): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

The invention relates to a herbal medicament and a preparation method thereof, and specifically relates to a medicament for tranquilizing, heat clearing and detoxifying and its preparation method. The medicament of the invention comprises by weight: 1-5 parts of artificial bezoar, 1-15 parts of pearl, 1-15 parts of borneol, 1-5 parts of bamboo juice, 1-15 parts of cinnabar, 5-100 parts of rheum officinale, 5-20 parts of curcuma tuber, 1-6 parts of natural indigo, 5-20 parts of grass-leaved sweetflag rhizome, 1-10 parts of Arisaema cum Bile, 1-5 parts of concretio silicea bambusae, 5-150 parts of buffalo horn slice, 1-15 parts of pearl layer powder, 1-5 parts of scutellaria extract, and 1-5 parts of berberis root extract. With natural plant medicine as the raw materials, the medicament is prepared according to the combined effect of a traditional Chinese medicine theoretical formula, and can be used to treat hyperthermia, dysthesia and uneasiness, insomnia and dreamful sleep, coma and delirium, infantile convulsion and twitch, epilepsy, headache and vertigo. The medicament provided in the invention can be taken for a long term without the adverse reactions of listlessness, trance, loss of short memory and the like.

The invention discloses an extraction and expression mode of a pain component in brain waves. The extraction and expression mode is a method for extracting characteristic components of feelings related to pains, labor pains, anxiety, tension, delirium, oblivion and comfort in the brain waves by acquiring a brain wave signal in real time and utilizing a mathematic calculation algorithm of discrete signal processing, and the method is expressed into an expression mode of dimensionless data of 0-100. By utilizing a signal sensing technology of electrophysiology to acquire a brain wave signal and calculate and analyze the signal, the characteristic index is found and extracted, through normalization processing, a quantitative numerical value for measuring the characteristic index is obtained, and technical means and application equipment for real-time pain measurement are formed. According to the extraction and expression mode of the pain component in the brain waves, a powerful support means is provided for scientific study of pain treatment and a management method, and the extraction and expression mode has important practical value in the aspects of analyzing a medicine curative effect, summarizing a treatment method, adjusting a treatment scheme, studying and analyzing a pain mechanism, collecting large sample long-time clinical pain relevant information and the like.

The invention relates to a medicine composite for treating cytomegalovirus, which comprises the following components in parts by weight: 62-95 parts of radix isatidis, 38-57 parts of honeysuckle, 5-20 parts of salvia miltiorrhiza, 16-35 parts of rhizoma atractylodis, 3-7 parts of alisma orientale and 22-43 parts of rhubarb. The taste of the radix isatidis is bitter and cold, and the radix isatidis enters the hepatic blood points and stomach blood points and is used for clearing away heat and toxic material and cooling blood; the taste of the honeysuckle is sweet and cold, the honeysuckle enters the lung channel and the stomach channel and is used for clearing away heat and toxic material; the taste of the rhizoma atractylodis is bitter and mild, the rhizoma atractylodis enters the spleen channel and the stomach channel and is used for invigorating the spleen, eliminating dampness, dispelling melancholy and avoiding dirty; the taste of the alisma orientale is sweet and cold, and the alisma orientale enters the kidney channel and the urinary bladder channel; and the taste of the rhubarb is bitter and cold, and the rhubarb enters the stomach channel, the spleen channel, the intestine channel, the liver channel and the pericardium channel. The medicine composite has the efficacy of purgating heat and bowels and is used for treating gastrointestinal real hot stagnancy, constipation, abdominal swelling, unpalpable abdominal pain, even high fever, coma and delirium like large chengqi decoction, or cold settling constipation due to Spleen Yang deficiency like spleen warming soup. The medicine has the characteristics of short treatment period, quick response, small side effect and the like.

The invention relates to a medicinal injection for treating delirium and a preparation method thereof, and relates to application of poloxamer to the preparation of refreshment calming injections. The medicinal injection is processed by using 7.5 parts of musk, 30 parts of turmeric root-tuber, 1 part of borneol, 30 parts of bupleurum, gardenia and 1 to 200 parts of poloxamer serving as a solubilizer.

The present invention relates to novel compounds of the Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

Disclosed is a pharmaceutical composition comprising a compound represented by the formula (I)or a pharmaceutically acceptable salt thereof as an active ingredient, which has an antagonistic activity on a melanin-concentrating hormone receptor. The pharmaceutical composition is useful, due to its antagonistic activity on a MCH receptor, for the prevention or treatment of a disease such as depression, anxiety disorders (e.g., generalized anxiety disorder, post traumatic stress disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder), attention deficit disorder, mania, manic-depressive disorder, schizophrenia, mood disorders, stress, sleep disorder, attacks, memory impairment, cognitive impairment, dementia, amnesia, delirium, obesity, eating disorder, appetite disorder, hyperphagia, bulimia, cibophobia, diabetes, a cardiovascular diseases, hypertension, dyslipidemia, cardiac infarction, movement disorder (e.g., Parkinson's disease, epilepsy, convulsion, tremor), drug abuse and drug addiction.

The invention discloses a Xingnaojing injection and a preparation method thereof. The Xingnaojing injection is prepared from raw materials in parts by weight as follows: 7.5 parts of musk, 30 parts of turmeric root tuber, 30 parts of cape jasmine fruits, 1 part of borneol, 8 parts of sodium chloride for injection, 0.1-0.5 parts of a stabilizer and 0.1-1 part of an antioxidant. According to the Xingnaojing injection and the preparation method thereof, the stabilizer and the antioxidant are added to the preparation process of the injection, the quality stability of the Xingnaojing injection is improved, the stabilizer further has a solubilization function and increases content of effective ingredients in the Xingnaojing injection, and the prepared Xingnaojing injection has functions of clearing away heat and fire, cooling blood, eliminating toxins and inducing resuscitation, and can be used for treating epidemic encephalitis, hepatic coma, the symptom of heat entering construction-blood, the symptom of invasion of pericardium by heat, high fever, dysphoria, coma and delirium, deep red tongue, rapid pulse and the like.

The invention provides a method for predicting delirium through artificial intelligence, and belongs to the field of critical patient evaluation. The method comprises the steps: related data of a patient and a hospital are included through a structured language; feature variables are screened based on a random forest, and a prediction model is constructed through regularization logistic regression, K nearest neighbor, a support vector machine, the random forest, limit gradient lifting and a deep neural network algorithm; and through prediction probabilities of different methods, ensemble learning is carried out through a limit gradient lifting algorithm to finally predict whether a critical patient has delirium or not, and the occurrence probability of the delirium is further calculated. According to the method, patient data and hospital feature information are utilized as much as possible, and individualized evaluation for predicting the critical patient is carried out, so that prediction bias caused by a certain model is weakened, and prediction accuracy is improved.

The present invention relates to a monitoring system (1, 2, 3) and a corresponding monitoring method for monitoring a patient and detecting delirium of the patient in an unobtrusive manner without the need of on-body sensors. The proposed monitoring system comprises a monitoring unit (10) for obtaining image data (30) of the patient over time, an image analysis unit (12) for detecting motion events of the patient from the obtained image data (30), an evaluation unit (14) for classifying the detected motion events into delirium-typical motion events and non-delirium-typical motion events, and a delirium determination unit (16) for determining a delirium score (32) from the duration, intensity, type, location and / or occurrence of delirium-typical motion events, said delirium score (32) indicating the likelihood and / or strength of delirium of the patient.

The present invention encompasses novel substituted pyrimidine compounds of Formula (I): which act as MCH receptor antagonists. These compounds are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

The invention provides a toxin-expelling and skin-nourishing pill, wherein the prescription thereof is as follows: 900g of semen lepidii, 200g of euphorbia kansui, 200g of Chinese parsley, 500g of fermented soybean, 300g of almond, 500g of rhizoma sparganii, 500g of curcuma zedoary, 500g of rheum officinale, 500g of smoked plum, 400g of granatum, and 500g of trogopterus dung. The toxin-expelling and skin-nourishing pill is mainly used for curing the retention and the fever accompanied by fear of internal organs, constipation, various diarrheas, hydroncus, the heart-qi, hernia, boil and furuncle, toothache caused by excess fire, hot eyes and pain, thermojunction in chest, heart attacked by toxin fire, delirium, and obsession caused by diseases, can mediate the internal dysbolism caused by various retentions of internal organs, can resume normal metabolization in a short time, can fast expel the internal toxin, particularly can fast dispel boil and furuncle, erysipelas, toxic blain, toxic boil and the like, can clean up diseases such as vexation, dryness heat and the like in climacterium, smoothes urination and defecation, removes hydroncus, cures hernia, supplements the heart-qi, and eliminates all internal and external solid toxin heat diseases.

The invention provides a children delirium prediction method and system based on electroencephalogram signals. The method comprises the following specific processing steps: 1, collecting multi-channel electroencephalogram data of children in a waking period after an anesthesia operation; 2, preprocessing the acquired multichannel electroencephalogram data; 3, extracting multi-domain features of the preprocessed multi-channel electroencephalogram data; and 4, inputting the multi-domain features into an SVM classifier to obtain a delirium prediction result. The system comprises an electroencephalogram data acquisition module, a preprocessing module, a feature extraction module and a classification module. The invention provides the children delirium prediction method and the system thereof, and the method and system are objective, are high in accuracy, and are beneficial to early warning and timely treatment of clinical children delirium.

The invention relates to the technical field of preparation for traditional Chinese medicines, in particular to a traditional Chinese medicine for treating febrile diseases and a preparation method thereof. The traditional Chinese medicine is prepared from raw materials including calculus bovis factitius, muscone, cornu bubali concentrated powder, scutellaria baicalensis, gardenia, radix curcumae, andrographis paniculata, rhizoma coptidis, broneolum syntheticum and pearl powders, and the raw materials is mainly subjected to smashing, decoction and alcohol extraction to prepare dosage forms such as powders, tablets, capsules, honeyed pills, and watered pills. The medicine provided by the invention is applicable for the treatment of symptoms caused by warm heat diseases, such as continuous high fever, dysphoria, hotness, convulsions, as well as coma and delirium, and is free from toxic substances.

The invention belongs to the technical field of medicine, and particularly relates to application of ketorolac tromethamine in preparation of a drug for treating mental diseases. The medicine is particularly applicable to treatment of depression and delirium patients, pharmacological experiments of animal models find that the drug prepared with ketorolac tromethamine as an active component can significantly improve distraction and depression states of model mice and has significant therapeutic effects on mental disease patients suffering from the symptoms.

The invention relates to a delirium risk monitoring method based on a delirium dynamic prediction model. The delirium risk monitoring method at least comprises one or more of the following steps of carrying out delirium consciousness fuzzy quick evaluation of a to-be-evaluated object for at least one time; calling a dominant factor and a recessive factor related to the to-be-evaluated object in amedical information management system by a delirium factor processing module, and generating a label required by a delirium risk monitoring module according to the attribute of the dominant factor and / or the attribute of the recessive factor; based on the generated label, enabling the delirium risk monitoring module to obtain a plurality of case information groups matched with the to-be-evaluatedobject in a cloud platform in an information interaction mode with the cloud platform; and enabling the delirium risk monitoring module to perform calculation by using the delirium dynamic predictionmodel according to the obtained multiple case information groups to obtain delirium risk prediction of the to-be-evaluated object.

The invention provides modeling of PACU adult high-activity delirium prediction. Patients who enter a hospital for surgical treatment in the same time period and then enter a PACU for observation areselected; according to the diagnosis standard of PDHA, the patients are set into two groups: a PDHA group and a non-PDHA group; the observation time is from the period when each patient enters the PACU to the period when the patient leaves the PACU after the operation, and two sets of patient data are collected in a retrospective mode through an Access database; the sorted and collected research data are randomly matched by stata15 software according to a ratio of 2:1, and the research data is divided into training set data and verification set data; statistics and analysis are carried out byusing an R language, and risk factors are screened by using step-by-step logistic regression, so that an adult postoperative early-stage high-activity delirium prediction model is constructed. The method has the advantages that the constructed PACU adult high-activity delirium prediction model is good in prediction efficiency, and visual and graphical screening of adult high-activity delirium after PACU operation can be achieved.

The invention relates to a medicinal injection for treating delirium and a preparation method thereof, and relates to application of poloxamer to the preparation of refreshment calming injections. The medicinal injection is processed by using 7.5 parts of musk, 30 parts of turmeric root-tuber, 1 part of borneol, 30 parts of bupleurum, gardenia and 1 to 200 parts of poloxamer serving as a solubilizer.

Disclosed is a method of determining a subject's susceptibility to by collecting a biological sample from the subject; determining the methylation status of at least one CpG sequence in the biological sample from the subject; and comparing the methylation status in the biological sample to an established threshold and determining whether or not the subject is likely to suffer delirium.In certain aspects, the at least one CpG sequence is located in a gene selected from TNF-alpha, BNDF, GDNF, LDLRAD4, DAPK1, and IRF8

The invention discloses a drug for treating psychosis. The drug is finely prepared from the following crude drugs in parts by weight: 2-6 parts of bile arisaema, 2-5 parts of scorpion, 2-8 parts of antelope horns, 5-12 parts of rhubarb, 3-10 parts of senna leaves, 5-20 parts of compounds of glauber-salt and liquorice, 5-8 parts of acorus calamus, 0.5-1.5 parts of cinnabaris, 5-8 parts of nacre, 3-10 parts of juncus effuses, 2-10 parts of Chinese eaglewood, 1-6 parts of alum, 2-10 parts of gleditsia sinensis, 10-20 parts of fructus trichosanthis, 3-15 parts of radix curcumae, 6-15 parts of rhizoma cyperi, 3-15 parts of polygala tenuifolia, 10-20 parts of poria with hostwood, 5-15 parts of date seeds, 3-10 parts of scutellaria baicalensis and 10-15 parts of radix ophiopogonis. The drug has the effects on clearing phlegm and resuscitating, refreshing and clearing away the heart fire, eliminating convulsions and arresting convulsion, smoothing the liver and regulating vital energy, eliminating delirium and calming the nerves as well as clearing away heat and purging pathogenic fire. Compared with the prior art, the drug has the advantages of short course of treatment, high effect taking speed, high cure rate, no easiness for recurrence, no toxic or side effect, low cost, easiness for patients to accept, and the like.